In the case of semaglutide, the immune systems response might mistakenly target the medication, leading to skin inflammation
The three FDA-approved injection sites for subcutaneous GLP-1 administration are the abdomen, the front or outer thigh, and the back of the upper arm
Insurance typically covers all of these if you have a relevant diagnosis on file (obesity, pre-diabetes, type 2 diabetes)
While multiple randomized controlled trials (RCTs) have confirmed the short-term efficacy and safety of GLP-1 RAs, the long-term outcomes, particularly regarding sustained weight loss, weight regain, and safety profiles, remain areas of active investigation [6]
doi: 10.1016/j.molmet.2015.07.008 [DOI] [PMC free article] [PubMed] [Google Scholar] 71
Khi ngng s dng, ghrelin tng tr li, kch thch s thm n trong khi leptin gim, lm gim kh nng kim sot cm gic no